WO2004069207A3 - Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins - Google Patents

Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins Download PDF

Info

Publication number
WO2004069207A3
WO2004069207A3 PCT/US2004/003865 US2004003865W WO2004069207A3 WO 2004069207 A3 WO2004069207 A3 WO 2004069207A3 US 2004003865 W US2004003865 W US 2004003865W WO 2004069207 A3 WO2004069207 A3 WO 2004069207A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
antigenic molecule
fusion proteins
immunogenic
molecule complexes
Prior art date
Application number
PCT/US2004/003865
Other languages
French (fr)
Other versions
WO2004069207A2 (en
Inventor
Pramod K Srivastava
Original Assignee
Univ Connecticut Health Ct
Pramod K Srivastava
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut Health Ct, Pramod K Srivastava filed Critical Univ Connecticut Health Ct
Priority to EP04708279A priority Critical patent/EP1599223A4/en
Priority to AU2004208851A priority patent/AU2004208851A1/en
Priority to CA002515123A priority patent/CA2515123A1/en
Publication of WO2004069207A2 publication Critical patent/WO2004069207A2/en
Publication of WO2004069207A3 publication Critical patent/WO2004069207A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention relates to complexes and fusion proteins comprising a CD91 ligand and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides complexes comprising a CD91 ligand noncovalently bound to, or alternatively crosslinked to, an antigenic molecule. The invention also specifically provides fusion proteins comprising a CD91 ligand fused via a peptide bond to an antigenic molecule.
PCT/US2004/003865 2003-02-04 2004-02-04 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins WO2004069207A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04708279A EP1599223A4 (en) 2003-02-04 2004-02-04 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
AU2004208851A AU2004208851A1 (en) 2003-02-04 2004-02-04 Immunogenic CD91 ligand-antigenic molecule complexes and fusion proteins
CA002515123A CA2515123A1 (en) 2003-02-04 2004-02-04 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44477303P 2003-02-04 2003-02-04
US60/444,773 2003-02-04

Publications (2)

Publication Number Publication Date
WO2004069207A2 WO2004069207A2 (en) 2004-08-19
WO2004069207A3 true WO2004069207A3 (en) 2005-10-06

Family

ID=32850929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/003865 WO2004069207A2 (en) 2003-02-04 2004-02-04 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins

Country Status (4)

Country Link
EP (1) EP1599223A4 (en)
AU (1) AU2004208851A1 (en)
CA (1) CA2515123A1 (en)
WO (1) WO2004069207A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009233A2 (en) * 2005-07-18 2007-01-25 University Of Manitoba Peptide-based cytokine vaccines in the treatment of autoimmune and inflammatory diseases
RU2619187C2 (en) * 2012-12-05 2017-05-12 Тевакс Дженетикс Вэксин Ко., Лтд. Fusion proteins for application as immunogenic amplifying agents to induce antigen-specific t-cell response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
US7449557B2 (en) * 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors

Also Published As

Publication number Publication date
WO2004069207A2 (en) 2004-08-19
EP1599223A2 (en) 2005-11-30
CA2515123A1 (en) 2004-08-19
AU2004208851A1 (en) 2004-08-19
EP1599223A4 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
WO2004069206A3 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2002062377A3 (en) Combined use of factor vii polypeptides and factor viii polypeptides
WO2006010057A3 (en) Therapeutic peptides
WO2003090686A3 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2007022239A3 (en) Pharmaceutical formulations for sustained drug delivery
SI1180121T1 (en) Long lasting insulinotropic peptides
WO2003057134A8 (en) Specific binding agents of human angiopoietin-2
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2000078344A8 (en) Prion protein peptides and uses thereof
AU2210402A (en) Photochemical internalization for virus-mediated molecule delivery into the cyosol
WO2002098360A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2006062917A3 (en) Alpha thymosin peptides as cancer vaccine adjuvants
WO2007041285A3 (en) Complexes of inactivated pepsin fraction and heat shock protein
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
WO2006060021A3 (en) Bifunctional fusion proteins containing the flt3 ligand
AU2003203002A1 (en) Polymeric conjugates for delivery of mhc-recognized epitopes via peptide vaccines
PL1869185T3 (en) Conjugate comprising p21 protein for the treatment of cancer
WO2004069207A3 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
WO2004069208A3 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
WO2004069204A3 (en) Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2006103354A3 (en) Dermatological and/or cosmetic composition containing proteins of the sirt family
WO2002040518A8 (en) Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2515123

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004208851

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004208851

Country of ref document: AU

Date of ref document: 20040204

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2004708279

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004208851

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004708279

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004708279

Country of ref document: EP